NFRKB

NFRKB is a metazoan-specific subunit of the INO80 chromatin remodeling complex that functions as a potent inhibitor of the deubiquitylase UCH37 (UCHL5) through its DEUBAD domain, which exploits conformational plasticity of UCH37 to block ubiquitin binding and disrupt the active site via molecular mimicry (PMID:25702872, PMID:25702870). Reciprocally, UCHL5 stabilizes NFRKB by protecting it from ubiquitin-dependent proteasomal degradation, and this interaction is required for DNA double-strand break resection and homologous recombination repair (PMID:25194926). NFRKB associates with telomeres in ALT-pathway cancer cells, where its loss causes telomere dysfunction and reduced PML bodies (PMID:34591601). The lncRNA DRAIC negatively regulates NFRKB protein levels by binding UCHL5 and attenuating the stabilizing UCHL5–NFRKB interaction, linking NFRKB turnover to gastric cancer cell proliferation (PMID:32351584).

1. 2012 Low

   Computational analysis established that NFRKB is a metazoan-specific INO80 complex subunit whose DEUBAD domain shares common ancestry with the proteasomal RPN13 DEUBAD, predicting a role in regulating UCH37 deubiquitylase activity in a non-proteasomal context.

   Evidence Comparative genomics and domain architecture analysis

   PMID:22645167

   Open questions at the time

   • Purely computational prediction without experimental validation of the NFRKB–UCH37 interaction
   • No structural or biochemical data to confirm inhibitory versus activating function
   • Mechanism of NFRKB incorporation into INO80 unknown
2. 2012 Medium

   Structural characterization of an N-terminal domain of NFRKB revealed a novel winged-helix-like fold that does not bind DNA, establishing that NFRKB likely mediates its functions through protein–protein interactions rather than direct DNA recognition.

   Evidence X-ray crystallography and DNA binding assays

   PMID:22984442

   Open questions at the time

   • Binding partners for this domain not identified
   • Only one domain of the multi-domain protein was characterized
3. 2012 Medium

   NFRKB was shown to undergo sumoylation and nucleocytoplasmic redistribution in disease, with nuclear NFRKB activating AP1 signaling via c-jun upregulation and promoting genomic DNA hypomethylation, revealing transcription-regulatory consequences of NFRKB localization.

   Evidence Western blotting, immunofluorescence, subcellular fractionation, reporter assays, and bisulfite sequencing in minimal change nephrotic syndrome samples

   PMID:22291976

   Open questions at the time

   • Mechanism linking NFRKB to AP1 activation and DNA hypomethylation not defined
   • Findings from a single disease context; generalizability unclear
   • Sumoylation sites and functional consequences of sumoylation not mapped
4. 2014 High

   The discovery that UCHL5 deubiquitylates and stabilizes NFRKB, and that both proteins are required for DSB resection and homologous recombination, established the UCHL5–NFRKB axis as a functional unit in the DNA damage response.

   Evidence Multidimensional siRNA screen, reciprocal Co-IP, genetic epistasis by double knockdown, and HR repair assays

   PMID:25194926

   Open questions at the time

   • Ubiquitin sites on NFRKB mediating proteasomal degradation not mapped
   • E3 ligase targeting NFRKB not identified
   • Whether NFRKB's role in HR depends on its INO80 incorporation or UCH37 inhibition not distinguished
5. 2015 High

   Crystal structures of the NFRKB DEUBAD domain bound to UCH37, solved independently by two groups, revealed that NFRKB inhibits UCH37 by inducing a radically different enzyme conformation from the activating RPN13 DEUBAD and by mimicking ubiquitin to occlude the substrate-binding site, resolving the molecular basis of NFRKB's inhibitory function.

   Evidence Crystal structure determination, in vitro DUB activity assays, and mutagenesis from two independent laboratories

   PMID:25702870 PMID:25702872

   Open questions at the time

   • Physiological consequence of UCH37 inhibition by NFRKB within the INO80 complex not determined in vivo
   • Whether UCH37 has any catalytic role when bound to NFRKB in specific contexts remains unresolved
   • Regulation of the inhibitory interaction (e.g., post-translational modification switches) not explored
6. 2020 Medium

   The lncRNA DRAIC was identified as a negative regulator of NFRKB stability by competing for UCHL5 binding, establishing an RNA-mediated mechanism that controls NFRKB protein turnover and links NFRKB levels to gastric cancer cell proliferation and metastasis.

   Evidence RNA-IP, Co-IP, ubiquitination-IP, cycloheximide/MG132 chase, siRNA knockdown, lentiviral overexpression, and functional rescue in gastric cancer cells

   PMID:32351584

   Open questions at the time

   • DRAIC binding site on UCHL5 and competition mechanism not structurally defined
   • Findings from a single cancer type; relevance to other contexts unknown
   • Whether DRAIC regulation of NFRKB affects INO80 complex integrity not tested
7. 2021 Medium

   NFRKB was shown to associate with telomeres specifically in ALT-pathway cancer cells, where its depletion causes telomere dysfunction and loss of APBs (ALT-associated PML bodies), establishing a telomere-protective role for NFRKB in the ALT mechanism.

   Evidence Immunostaining, FISH co-localization, and siRNA knockdown with telomere phenotype readout in U2OS cells

   PMID:34591601

   Open questions at the time

   • Whether telomere association requires the INO80 complex or is an independent function not determined
   • Mechanism of telomere protection not defined (e.g., role in recombination, replication, or chromatin remodeling at telomeres)
   • Not tested in non-ALT telomere maintenance contexts

• It remains unknown how NFRKB coordinates its dual roles as a UCH37 inhibitor and INO80 complex subunit in vivo, which E3 ligase targets NFRKB for degradation, and whether NFRKB's telomere-protective and DNA repair functions are mechanistically linked through INO80 chromatin remodeling activity.
• E3 ligase responsible for NFRKB ubiquitylation unidentified
• In vivo function of UCH37 inhibition by NFRKB within the INO80 complex not established
• Relationship between telomere association and HR repair function unexplored